Clinical trial · Observational
Efficacy and Safety Evaluation of Traditional Chinese Medicine in the Treatment of Advanced Colorectal Cancer
NCT02923622CI-TRIAL-00024137unknownClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
Although patients of colorectal cancer use Traditional Chinese Medicine (TCM) herbal therapy extensively in China, no strong evidence exists to demonstrate the safety and survival outcomes of TCM herbal therapy combined with conventional western medicine for treatment of this disease. The purpose of this multi-center perspective cohort study is to evaluate the relationship between TCM herbal therapy and survival outcomes in patients with advanced colorectal cancer.
Conditions
Conditions (2)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Advanced Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
| Traditional Chinese Medicine | — | UNRESOLVED | — |
Interventions
Interventions (3)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Integrated traditional Chinese and Western medicine | Other | — | UNRESOLVED |
| Traditional Chinese medicine herbals | Other | — | UNRESOLVED |
| Western medicine | Other | — | UNRESOLVED |
Design
Arms and outcomes
Arms (3)
- label
- Traditional Chinese and Western medicine combined group
- interventionNames
- Other: Integrated traditional Chinese and Western medicine
- label
- Traditional Chinese medicine group
- interventionNames
- Other: Traditional Chinese medicine herbals
- label
- Western medicine group
- interventionNames
- Other: Western medicine
Primary outcomes (1)
- measure
- Overall survival
- timeFrame
- 3 years
Secondary outcomes (5)
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
- Maximum age
- 80 Years
Show eligibility criteria text
Inclusion Criteria: * histologically confirmed adenocarcinoma of the colon or rectum * TNM classification of stage IV disease according to American Joint Committee on Cancer * Between 18 and 80 years old * Progression or inability undergone conventional chemotherapy (Conventional chemotherapy regimen containing fluorouracil, oxaliplatin, irinotecan based chemotherapy, and all the above regimen should be used before) * Expected survival time is over 3 months * Signed informed consent Exclusion Criteria: * serious non-malignant diseases such as heart, renal, and hepatic illnesses * the presence of other types of malignancies * The patients can not take medicine for intestinal obstruction
References
Publications (1)
- DERIVEDHao TT, Xu Y, Cui N, Qu Q, Liang BY, Yuan JH, Zhao Y, Li QN, Lu F, Wu Y. Effectiveness and Safety Evaluation of Chinese Medicine in Treatment of Metastatic Colorectal Cancer after Chemotherapy Failure: Protocol of a Prospective Multicenter Cohort Study. Chin J Integr Med. 2021 Sep;27(9):674-679. doi: 10.1007/s11655-020-3420-0. Epub 2020 Aug 19. PMID 32820453